- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01206608
Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty
A Randomized, Double-Blind, Active-Control Study to Evaluate the Safety and Efficacy of a Single Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Augmentation Mammoplasty
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This was a Phase 2, parallel-group, active-control, randomized, double-blind study conducted to evaluate a single local administration of low dose or high dose of SKY0402 compared with 75 mg of bupivacaine HCl (i.e., Marcaine® 0.5%) in women undergoing bilateral, cosmetic, sub-muscular, augmentation mammoplasty under general anesthesia. Each subject was to serve as her own control.
A total of 40 subjects were randomized in a 1:1 ratio to receive one of the following regimens:
- Low-dose SKY0402 in one side and Marcaine 75 mg in the contralateral side.
- Mid-dose SKY0402 in one side and Marcaine 75 mg in the contralateral side.
Study drug was administered locally into the breast implant pocket at the end of surgery. After surgery, subjects were to receive standard treatment with acetaminophen 1000 mg three times daily and rescue analgesia with immediate-release oxycodone, as needed, for breakthrough pain.
Assessments of postoperative pain were conducted through 96 hours. Safety assessments were conducted including monitoring of local and systemic adverse events (AEs).
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Associates for Plastic Surgery
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Subjects who met all of the following criteria were eligible for inclusion in the study:
- Women, 18-40 years of age at the Screening Visit.
- Postmenopausal, surgically sterile, or willing to use an acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
- Scheduled to undergo primary, bilateral, sub-muscular, augmentation mammoplasty under general anesthesia.
- American Society of Anesthesiology (ASA) Physical Class 1-3.
- Able and willing to comply with all study visits and procedures.
- Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
- Willing and capable of providing written informed consent.
Exclusion Criteria:
Subjects were not eligible for the study if they met any of the following criteria:
- Pregnancy, nursing, or planning to become pregnant during the study or within one month after study drug administration.
- Body weight less than 50 kilograms.
- History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics or to opioid medication.
- Administration of an investigational product within 30 days or 5 elimination half-lives of such investigational product, whichever was longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
- History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
- Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicated an increased vulnerability to study drugs and procedures, and exposed the subject to an unreasonable risk as a result of participating in this clinical trial (e.g., severe hepatic insufficiency, hypotension, heart block, or severely impaired cardiac function).
In addition, the subject was ineligible to receive study drug if she met the following criterion during surgery:
- Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postoperative course.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Low-dose SKY0402 + bupivacaine HCl
Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
|
Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
|
Aktiv komparator: Mid-dose SKY0402 + bupivacaine HCl
Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
|
Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores
Tidsramme: Through 96 hours postdose
|
Assessments of postoperative pain were conducted through 96 hours and included pain intensity at rest (NRS-R) and with activity (NRS-A).
The prescribed activity was to consist of raising the arm, in full extension at the elbow and wrist, to a position parallel with the axis of the torso.
Pain intensity was scored on an 11-point scale, where 0 = no pain and 10 = worst possible pain.
|
Through 96 hours postdose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Adverse Events
Tidsramme: Through 30 days postdose
|
Adverse events were monitored through Day 8 and serious adverse events through Day 30.
|
Through 30 days postdose
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Kay Warnott, RN, ACNP, Pacira Pharmaceuticals, Inc
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Postoperative komplikationer
- Smerte
- Neurologiske manifestationer
- Smerter, postoperativ
- Lægemidlers fysiologiske virkninger
- Depressive midler til centralnervesystemet
- Agenter fra det perifere nervesystem
- Sensoriske systemagenter
- Bedøvelsesmidler
- Bedøvelsesmidler, lokale
- Bupivacain
Andre undersøgelses-id-numre
- SKY0402-C-210
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Postoperativ smerte
-
Wake Forest University Health SciencesRekruttering
-
University of California, San DiegoJohns Hopkins University; United States Department of Defense; The Cleveland... og andre samarbejdspartnereTilmelding efter invitationKirurgisk amputation af nedre ekstremiteter | Post-amputation Phantom Limb PainForenede Stater
-
Brugmann University HospitalTrukket tilbagePhantom Limb Pain (PLP) | Primær/sekundær arhyperalgesiBelgien
-
Quiropraxia y EquilibrioUniversidad Nacional Andres BelloAfsluttetMyofascial Trigger Point Pain (MTrP)Chile
-
East Carolina UniversityTrukket tilbage
-
Quiropraxia y EquilibrioIkke rekrutterer endnuMyofascial Trigger Point Pain (MTrP)Chile
-
Rijnstate HospitalSaluda Medical Pty LtdTilmelding efter invitationPolyneuropatier | Kronisk smertesyndrom | Multi Focal Pain | Mislykket nakkekirurgi syndromHolland
-
Oslo University HospitalUniversity of Oslo; Fysiofondet; Oslo Metropolitan UniversityRekrutteringGluteal tendinopati | Trochanterisk bursitis | Lateral hoftesmerter | GTPS - Greater Trochanteric Pain SyndromeNorge
-
University of KentuckyDonJoy OrthopedicsAfsluttetPostoperativ Quadriceps Svaghed | Postoperativ Quadriceps-hæmning | Overholdelse af postoperativ behandling | Postoperativ underekstremitetsfunktionForenede Stater
-
Ospedale Misericordia e DolceUkendtPostoperativ smerte | Thyroidektomi | Postoperativ kvalme og opkast | Postoperativ stemmefunktionItalien
Kliniske forsøg med SKY0402 + bupivacaine HCl
-
Pacira Pharmaceuticals, IncAfsluttetPostoperativ smerteForenede Stater
-
Pacira Pharmaceuticals, IncAfsluttet
-
Pacira Pharmaceuticals, IncAfsluttetPostoperativ smertebehandlingForenede Stater
-
Pacira Pharmaceuticals, IncAfsluttetSmerte | Nedsat leverfunktionPolen
-
Pacira Pharmaceuticals, IncAfsluttet
-
Mayo ClinicAfsluttetSmerter, postoperativ | Brachial Plexus BlokForenede Stater
-
Pacira Pharmaceuticals, IncAfsluttet
-
Pacira Pharmaceuticals, IncAfsluttetPostoperativ smertebehandlingForenede Stater
-
University of Texas Southwestern Medical CenterAfsluttetSkuldersmerterForenede Stater
-
Istanbul UniversityAfsluttetSmerter, postoperativKalkun